AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Jeffrey S. Weber

Stock and Other Ownership Interests: Biond, OncoC4, Instil Bio, Evaxion Biotech, Nexlmmune

Honoraria: Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Amgen, Roche, Celldex, CytomX Therapeutics, Novartis, Sellas Life Sciences, WindMIL, Takeda, Moderna Therapeutics, Jounce Therapeutics, Kirin Pharmaceuticals, Regeneron, Idera, Oncosec, Incyte, Nexlmmune, Instil Bio, Ultimovacs, OncoC4, Biond Biologics, Pfizer

Consulting or Advisory Role: Celldex, Bristol Myers Squibb, Merck, Genentech, Roche, Amgen, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo Recipient, CytomX Therapeutics Recipient, Novartis, Sellas Life Sciences, WindMIL Recipient, Jounce Therapeutics Recipient, Moderna Therapeutics, Kirin Pharmaceuticals Recipient, Protean Biodiagnostics, Idera, Oncosec, OncoC4, Incyte, Instil Bio, Biond Biologics, Ultimovacs Recipient, Pfizer, Nexlmmune

Research Funding: Bristol Myers Squibb (Inst), Merck (Inst), GlaxoSmithKline (Inst), Genentech (Inst), Astellas Pharma (Inst), Incyte (Inst), Roche (Inst), Novartis (Inst), NextCure (Inst), Moderna Therapeutics (Inst)

Patents, Royalties, Other Intellectual Property: Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker, named on a patent from Biodesix for a PD-1 antibody biomarker, named on a patent for 41BB induced TIL by Moffitt Cancer Center

Travel, Accommodations, Expenses: Bristol Myers Squibb, GlaxoSmithKline, Roche, Celldex, Amgen, Merck, AstraZeneca, Genentech, Novartis, Merck Sharp & Dohme

Michele Del Vecchio

Consulting or Advisory Role: Novartis, Bristol Myers Squibb, Merck, Pierre Fabre

James Larkin

Honoraria: Bristol Myers Squibb, Pfizer, Novartis, Incyte, Merck Serono, Eisai, touchlME, touchEXPERTS, Royal College of Physicians, Cambridge Healthcare research, RCGP, VJOncology, Agence Unik

Consulting or Advisory Role: Bristol Myers Squibb, Incyte, iOnctura, Apple Tree Partners, Merck Serono, Eisai, Debiopharm Group, Pierre Fabre, Ipsen, Roche, EUSA Pharma, Novartis, Aptitude Health, AstraZeneca, GlaxoSmithKline, Calithera Biosciences, Ultimovacs, Seattle Genetics, eCancer, Insel Gruppe, Pfizer, Goldman Sachs, MSD Oncology, Agence Unik

Research Funding: Pfizer (Inst), Novartis (Inst), MSD Recipient (Inst), Bristol Myers Squibb (Inst), Achilles Therapeutics (Inst), Roche (Inst), Nektar (Inst), Covance (Inst), Immunocore (Inst), AVEO (Inst), Pharmacyclics (Inst)

Travel, Accommodations, Expenses: Roche/Genentech, GlaxoSmithKline, Pierre Fabre

Victoria Atkinson

Honoraria: Bristol Myers Squibb, Novartis, Merck Sharp & Dohme, Fabre, Roche/Genentech, Merck Serono, Nektar, QBiotics, Provectus Biopharmaceuticals

Consulting or Advisory Role: Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre Fabre, Roche, QBiotics

Speakers' Bureau: Roche/Genentech, Bristol Myers Squibb, Novartis, Merck Sharp & Dohme, Merck Serono

Expert Testimony: Bristol Myers Squibb/Celgene

Travel, Accommodations, Expenses: Bristol Myers Squibb, OncoSec, Derek Sharp & Dohme, Fabre

Michael Schenker

Research Funding: Bristol Myers Squibb, Roche, NISD, Amgen, Pfizer/EMD Serono, Lilly, Astellas Pharma, AstraZeneca, GlaxoSmith Kline, Regeneron, Novartis, AbbVie, Gilead Sciences, Sanofi/Regeneron, Dylan, BIOVEN, Clovis Oncology, Tesaro, Five Prime Therapeutics

Travel, Accommodations, Expenses: Bristol Myers Squibb

Helen Gogas

Honoraria: Bristol Myers Squibb, USD Oncology, Pierre Fabre, Sanofi/Regeneron

Consulting or Advisory Role: Bristol Myers Squibb, USD Oncology, Amgen, Fabre, Sanofi/Regeneron

Research Funding: Bristol Myers Squibb (Inst), Roche (Inst), USD Oncology (Inst), Amgen (Inst), Novartis (Inst), lovance Biotherapeutics (Inst)

Travel, Accommodations, Expenses: Bristol Myers Squibb, USD, Amgen, Pfizer

Stéphane Dalle

Employment: Sanofi Pasteur (I)

Stock and Other Ownership Interests: Sanofi (I)

Consulting or Advisory Role: Bristol Myers Squibb (Inst), N!SD (Inst)

Speakers' Bureau: Bristol Myers Squibb (Inst), N!SD (Inst)

Research Funding: Bristol- Myers Squibb (Inst), Merck Sharp & Dohme (Inst), Roche (Inst)

Travel, Accommodations, Expenses: Bristol Myers Squibb

Nicolas Meyer

Consulting or Advisory Role: Bristol Myers Squibb, USD Oncology, Novartis, Pierre Fabre, Sun Pharma, Nlerckle GmbH

Research Funding: Bristol Myers Squibb (Inst), USD Oncology (Inst)

Paolo A. Ascierto

Stock and Other Ownership Interests: PrimeVax

Consulting or Advisory Role: Bristol Myers Squibb, Roche/Genentech, Merck Sharp & Dohme, Novartis, Array BioPharma, Merck Serono, Pierre Fabre, Incyte, Medlmmune, Astra Zeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, AIkermes, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Ta kis Biotech, Lunaphore Technologies, Seattle Genetics, ITeos Therapeutics, N!edicenna, Bio-AI Health, ValoTx

Research Funding: Bristol Myers Squibb (Inst), Roche/Genentech (Inst), Array BioPharma (Inst), Sanofi (Inst), Pfizer (Inst)

Travel, Accommodations, Expenses: Merck Sharp & Dohme, Pfizer

Shahneen Sandhu

Honoraria: Bristol Myers Squibb (Inst), Derek (Inst), Astra Zeneca (Inst)

Consulting or Advisory Role: Astra Zeneca (Inst), Merck Sharpe & Dohme (Inst), Bristol Myers Squibb/Roche (Inst)

Speakers' Bureau: Bristol Myers Squibb (Inst), Nlerck (Inst), Roche/Genentech, Astra Zeneca (Inst)

Research Funding: Amgen (Inst), Astra Zeneca (Inst), Merck (Inst), Endocyte/Advanced Accelerator Applications (Inst), Genentech/Roche (Inst), Novartis (Inst), Pfizer (Inst), Senhwa Biosciences (Inst), Roche/Genentech (Inst)

Uncompensated Relationships: AAA/Endocyte/Novartis (Inst)

Thomas Eigentler

Honoraria: Bristol Myers Squibb, Novartis

Consulting or Advisory Role: Bristol- Myers Squibb, Novartis, Sanofi, Pierre Fabre

Ralf Gutzmer

Honoraria: Bristol-Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, Novartis, Derek Serono, AImirall Hermal GmbH, Amgen, Sun Pharma, Fabre, Sanofi/Regeneron, Immunocore

Consulting or Advisory Role: Bristol Myers Squibb, Derek Sharp & Dohme, Roche/Genentech, Novartis, AImirall Hermal GmbH, 4SC, Amgen, Fabre, Merck Serono, Sun Pharma, Sanofi, Immunocore

Research Funding: Pfizer (Inst), Novartis (Inst), Johnson & Johnson (Inst), Amgen (Inst), Merck Serono (Inst), Sun Pharma (Inst), Sanofi (Inst)

Travel, Accommodations, Expenses: Bristol Myers Squibb, Roche, Merck Serono, Fabre, Sun Pharma

Jessica C. Hassel

Honoraria: USD, Novartis, Sanofi, AImirall Hermal GmbH, Sun Pharma, Roche Pharma AG, Bristol Myers Squibb Foundation, Kline, Amgen, Fabre

Consulting or Advisory Role: Sun Pharma, Sanofi Aventis GmbH, MSD

Research Funding: Bristol Myers Squibb (Inst), Novartis (Inst), Immunocore (Inst), BioNTech (Inst), 4SC (Inst), Philogen (Inst), Idera (Inst), Genentech/Roche (Inst), lovance Biotherapeutics (Inst), Pierre Fabre (Inst), Regeneron (Inst), Sanofi (Inst), Nektar (Inst), Sun Pharma (Inst)

Caroline Robert

Stock and Other Ownership Interests: RiboNexus

Consulting or Advisory Role: Bristol Myers Squibb, Roche, Novartis, Pierre Fabre, MSD, Sanofi, AstraZeneca, Pfizer

Research Funding: Novartis (Inst), Phio Pharmaeutical (Inst)

Matteo S. Carlino

Honoraria: Bristol Myers Squibb, USD, Novartis

Consulting or Advisory Role: Bristol Myers Squibb, USD, Amgen, Novartis, Fabre, Roche, IDEAYA Biosciences, Sanofi, Merck Serono, Regeneron, QBiotics, OncoSec, Nektar

Anna Maria Di Giacomo

Consulting or Advisory Role: Bristol Myers Squibb, Pierre Fabre, Sanofi, MSD Oncology, GlaxoSmith Kline

Travel, Accommodations, Expenses: Pierre Fabre, Bristol Myers Squibb

Marcus O. Butler

Honoraria: Roche, Merck, Bristol Myers Squibb, Novartis

Consulting or Advisory Role: Merck, Bristol Myers Squibb, Novartis, Immunovaccine, Immunocore, Adaptimmune, EMD Serono, GlaxoSmith Kline, Genzyme, GlaxoSmith Kline, Sanofi, La Roche Posay, Sun Pharma, Instil Bio, lovance Biotherapeutics, Pfizer, Adaptimmune, Medison

Research Funding: Merck, Takara Bio

Expert Testimony: Merck

Eva Muñoz-Couselo

Honoraria: BMS, Novartis, Pierre Fabre, Roche, Sanofi, MSD

Consulting or Advisory Role: Bristol Myers Squibb/Celgene, Novartis, Roche, Pierre Fabre, USD, MSD, Sanofi

Speakers' Bureau: Bristol Myers Squibb/Celgene, Fabre, Sanofi, USD, Novartis

Michael P. Brown

Honoraria: BNS Australia, USD Oncology, Novartis

Consulting or Advisory Role: Bristol Myers Squibb (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), Cartherics (Inst)

Research Funding: Bristol Myers Squibb (Inst), Merck Sharp & Dohme (Inst), Pharmaust (Inst), Zucero Therapeutics (Inst), CStone Pharmaceuticals (Inst)

Piotr Rutkowski

Honoraria: Bristol Myers Squibb, MSD, Novartis, Roche, Pfizer, Pierre Fabre, Sanofi, Merck

Consulting or Advisory Role: Novartis, Blueprint Medicines, Bristol Myers Squibb, Pierre Fabre, MSD, Amgen

Speakers' Bureau: Pfizer, Novartis, Pierre Fabre

Research Funding: Novartis (Inst), Roche (Inst), Bristol Myers Squibb (Inst)

Travel, Accommodations, Expenses: Orphan Europe, Pierre Fabre

Andrew Haydon

Honoraria: Novartis, Merck, Novartis

Consulting or Advisory Role: Novartis, Merck Sharp & Dohme, Bristol Myers Squibb

Speakers' Bureau: Novartis, Derek, Bristol Myers Squibb

Expert Testimony: BUS

Jean-Jacques Grob

Consulting or Advisory Role: BMS, MSD Oncology, Roche/Genentech, Novartis, Amgen, Pierre Fabre, Merck KGaA, Sun Pharma, Sanofi, Roche, Philogen, Ultmovacs

Speakers' Bureau: Novartis

Travel, Accommodations, Expenses: BMS, USD Oncology, Novartis, Pierre Fabre

Jacob Schachter

Honoraria: Bristol Myers Squibb, MSD

Consulting or Advisory Role: MSD, Bristol Myers Squibb

Travel, Accommodations, Expenses: Bristol Myers Squibb

Paola Queirolo

Consulting or Advisory Role: Roche/Genentech, Novartis, USD, Bristol Myers Squibb, Pierre Fabre, Sanofi, Sun Pharma Advanced Research Company, Merck Serono

Travel, Accommodations, Expenses: MSD Oncology, Sanofi/Regeneron

Luis de la Cruz-Merino

Consulting or Advisory Role: Roche, MSD Oncology, Bristol Myers Squibb, Gilead Sciences, AstraZeneca, Incyte

Research Funding: Roche (Inst), Celgene (Inst)

Travel, Accommodations, Expenses: Roche

Andre van der Westhuizen

Consulting or Advisory Role: MSD Oncology, Novartis

Research Funding: Merck Serono

Travel, Accommodations, Expenses: Bristol Myers Squibb, Roche/Genentech, Novartis

Alexander M. Menzies

Consulting or Advisory Role: USD Oncology, Novartis, Pierre Fabre, Bristol Myers Squibb, Roche, QBiotics

Sandra Re

Stock and Other Ownership Interests: Bristol Myers Squibb

Tuba Bas

Employment: Bristol Myers Squibb, Merck, Fiore Healthcare Advisors (I)

Stock and Other Ownership Interests: Merck Sharp & Dohme, Bristol Myers Squibb (I)

Consulting or Advisory Role: Healthcare Advisors (I)

Travel, Accommodations, Expenses: Merck Sharp & Dohme, Fiore Healthcare Advisors (I)

Veerle de Pril

Employment: Bristol Myers Squibb

Stock and Other Ownership Interests: Bristol Myers Squibb

Julia Braverman

Employment: Bristol Myers Squibb

Stock and Other Ownership Interests: Bristol Myers Squibb

Travel, Accommodations, Expenses: Bristol Myers Squibb

Daniel J. Tenney

Employment: Bristol Myers Squibb Foundation

Stock and Other Ownership Interests: Bristol Myers Squibb Foundation

Travel, Accommodations, Expenses: Bristol Myers Squibb/Celgene

Hao Tang

Employment: Bristol Myers Squibb

Stock and Other Ownership Interests: Bristol Myers Squibb

Georgina V. Long

Honoraria: BMS, Fabre

Consulting or Advisory Role: Agenus, Amgen, Array BioPharma, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion Biotech, Hexal AG (Sandoz Company), Highlight Therapeutics, Innovent USA Inc, Merck Sharp & Dohme, Novartis, OncoSec Medical Australia, PHMR Limited, Pierre Fabre, Provectus, QBiotics, Regeneron

No other potential conflicts of interest were reported.